Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hyman

Showing results (291-300 of 401) with videos related to

Pageof 41
Sort By:
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
The American Journal of Surgical Pathology|September 5, 2020
Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic DifferentiationPier Selenica, Niamh Conlon, Carlene Gonzalez, et al.
The American Journal of Surgical Pathology|March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of FibrosarcomaSarah Chiang, Paolo Cotzia, David M Hyman, et al.
Pageof 41

Showing results (291-300 of 401) with videos related to

Sort By:
Pageof 41
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
Cancer Discovery|February 8, 2020
Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> <sup>V600</sup>-Mutant Non-Melanoma CancersVivek Subbiah, Igor Puzanov, Jean-Yves Blay, et al.
Cancers|November 7, 2020
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative AnalysisAntoine Italiano, Shivani Nanda, Andrew Briggs, et al.
The Lancet. Oncology|March 30, 2019
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trialVicky Makker, Drew Rasco, Nicholas J Vogelzang, et al.
Current Problems in Cancer|April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving LarotrectinibShivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
Investigational New Drugs|January 3, 2021
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancersJ Wu, D Liu, M Offin, et al.
The American Journal of Surgical Pathology|September 5, 2020
Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic DifferentiationPier Selenica, Niamh Conlon, Carlene Gonzalez, et al.
The American Journal of Surgical Pathology|March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of FibrosarcomaSarah Chiang, Paolo Cotzia, David M Hyman, et al.
Pageof 41